Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination With Temozolomide in Patients With Relapsed Solid Tumors and Lymphomas

Trial Profile

A Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination With Temozolomide in Patients With Relapsed Solid Tumors and Lymphomas

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 13 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Methoxyamine hydrochloride (Primary) ; Temozolomide (Primary)
  • Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Lymphoma; Non-small cell lung cancer; Ovarian cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 05 Oct 2023 Status changed from recruiting to completed.
    • 06 Jun 2023 Results of GCOC cohort (n=9; enrolled as of 12/23/2022) assessing efficacy and safety of the combination TRC102 and TMZ in patients with granulosa cell ovarian cancer, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
    • 30 May 2023 According to a TRACON Pharmaceuticals media release, company will present trial-in-progress posters in patients with granulosa cell ovarian cancer at the upcoming American Society of Clinical Oncology (ASCO) 2023 annual meeting, being held June 2-6, 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top